# US 2026/0062412 A1 · Nitrogen-containing heterocyclic compound having myt1 inhibitory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062412 A1
- Document ID: US20260062412A1
- Status: Published application
- Kind: A1
- Application number: 19/308,769
- Filed: 2025-08-25
- Published: 2026-03-05
- Earliest claimed: 2023-02-28
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Toshihiro AOKI; Takashi CHIBA; Masami KOCHI; Masaki TOMIZAWA; Yoshihisa MURATA; Eigo SUYAMA
- Web page: https://patentgrep.com/patent/US20260062412A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 221/10: Aza-phenanthrenes
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 471/14: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 7/0812: {comprising a heterocyclic ring}
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Provided is a compound having new MYT1 inhibitory activity or a salt thereof, or a solvate thereof. A compound represented by the formula (1): wherein R4 is selected from the group consisting of optionally substituted C6-C10 aryl (R4A), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R4HA); R5 and R6, together with the atoms to which they are attached, form an optionally substituted Ring D; Ring D is selected from the group consisting of a 3- to 10-membered monocyclic cycloaliphatic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (DHA); and any two adjacent substituents on Ring D, together with the atoms to which they are attached, may form optionally substituted Ring E, or a salt thereof, or a solvate thereof.

## Claims

### Claim 1

A compound selected from the following compounds, or a salt thereof, or a solvate thereof:
3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one,
3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, and
3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one.

### Claim 2

A compound, or a salt thereof, or a solvate thereof, wherein the compound is 3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one.

### Claim 3 (depends on 2)

The solvate according to claim 2, which is 3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one hydrochloride monohydrate.

### Claim 4 (depends on 2)

A pharmaceutical composition comprising the compound according to claim 2, or the salt thereof, or the solvate thereof.

### Claim 5 (depends on 3)

A pharmaceutical composition comprising the solvate according to claim 3.

### Claim 6 (depends on 2)

A method for treating cancer comprising administering an effective amount of the compound according to claim 2, or the salt thereof, or the solvate thereof, to a subject.

### Claim 7 (depends on 3)

A method for treating cancer comprising administering an effective amount of the solvate according to claim 3 to a subject.

### Claim 8

A compound, or a salt thereof, or a solvate thereof, wherein the compound is 3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one.

### Claim 9 (depends on 8)

The salt according to claim 8, which is 3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one hydrochloride.

### Claim 10 (depends on 8)

A pharmaceutical composition comprising the compound according to claim 8, or the salt thereof, or the solvate thereof.

### Claim 11 (depends on 9)

A pharmaceutical composition comprising the salt according to claim 9.

### Claim 12 (depends on 8)

A method for treating cancer comprising administering an effective amount of the compound according to claim 8, or the salt thereof, or the solvate thereof, to a subject.

### Claim 13 (depends on 9)

A method for treating cancer comprising administering an effective amount of the salt according to claim 9 to a subject.

### Claim 14

A compound, or a salt thereof, or a solvate thereof, wherein the compound is 3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one.

### Claim 15 (depends on 14)

The solvate according to claim 14, which is 3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one hydrochloride monohydrate.

### Claim 16 (depends on 14)

A pharmaceutical composition comprising the compound according to claim 14, or the salt thereof, or the solvate thereof.

### Claim 17 (depends on 15)

A pharmaceutical composition comprising the solvate according to claim 15.

### Claim 18 (depends on 14)

A method for treating cancer comprising administering an effective amount of the compound according to claim 14, or the salt thereof, or the solvate thereof, to a subject.

### Claim 19 (depends on 15)

A method for treating cancer comprising administering an effective amount of the solvate according to claim 15 to a subject.
